All News

RheumNow Podcast square

Higher Cancer Rates (8.16.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, noting his concerns about diet, cancer, ILD, death and dosing challenges.

Read Article
RheumNow Podcast square

Depends on Where You’re Looking (8.9.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.

Read Article
gout,podagra,MTP

Gout Forecast: 70% Increase by 2050

Jack Cush, MD

The Global Burden of Diseases, Injuries, and Risk Factors Study of 2021 has forecasted prevalence of gout to increase by 70% by 2050. In the USA, the prevalence of gout is estimated to be 10.3 million. As of 2020, 55.8 million people globally had gout, with a prevalence of 659.3 per 100 000 (this represents a 22.5% increase since 1990).

Read Article
RheumNow Podcast square

Lead with Lupus (8.2.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com - leading with lupus because everyone wants to know about lupus!

Read Article
knee.calcinosis.inflammation

Frequency and Features of CPPD

Jack Cush, MD

An international cohort study of patients with calcium pyrophosphate deposition (CPPD) disease, i.e., recurrent acute CPP crystal arthritis, chronic CPP crystal inflammatory arthritis, and crowned dens syndrome (CDS) identifies both acute and chronic inflammatory phenotypes, each with distinctive clinical and imaging diagnostic features.

Read Article
CPPDwrist.JPG

Review of Calcium Pyrophosphate Deposition Disease

Jack Cush, MD

Lancet Rheumatology has published a review of Calcium pyrophosphate deposition (CPPD) disease - a chronic inflammatory and degenerative crystal arthropathy that increases with aging.

Read Article
RheumNow Podcast square

Best Rheumatologists (7.19.2024)

Jack Cush, MD

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Read Article
RheumNow Podcast square

Pollution and Autoimmunity (7.12.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
AR882, a URAT1 inhibitor, was given FDA Fast Track designation for potential treatment of clinically visible tophi in patients with gout. In the US 13 mill have gout & 2 mill have visible tophi. AR882 was presented at EULAR24 https://t.co/StvD3iz9AD https://t.co/G9SzxJysSD https://t.co/KcUSPVb5pn

Links:

Dr. John Cush RheumNow ( View Tweet)
From 25K prediabetics, 1,521 had serial serum Uric acid measures. Predictors of increaed SU levels included Older age, male sex, greater BMI, and higher HbA1c. Those w/ a BMI ≥30 kg/m2 exhibited higher SU levels https://t.co/ztp8M781Dw https://t.co/PNaZxMIOlG

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 16 RCTs shows febuxostat reduces the risk of kidney events (RR = 0.56, 95% CI 0.37-0.84, p = 0.006) and a slower decline in eGFR (vs controls) https://t.co/9YAxTrHFVQ https://t.co/ZyRE7R6P4a

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/GV6WjsqZBH https://t.co/9l9qyJpg3I

Links:

Dr. John Cush RheumNow ( View Tweet)
EMR study looked at NIDDM & 4 indicators of #Obesity (waist circumference, waist/hip ratio, BMI, & visceral fat area -- 600 gout pts vs 9,935 controls shows all obesity measures signif incr odds of #Gout (OR 1.775, 1.691, 1.858, & 1.578, respectively) https://t.co/JJn5txgxiN https://t.co/tgnWWl9COe

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout Forecast: 70% Increase by 2050 The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) of 2021 has forecasted prevalence of gout to increase by 70% by 2050. https://t.co/7OSQXSBtUc https://t.co/p9hkO5xzAa

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Biobank 11+ yr study of 5728 incident gout pts - light alcohol decreased in gout incidence among females (HR 0.78). Light red wine also reduced gout risk, whereas beer or cider, champagne or white wine, and spirits increased the gout risk at any dose. https://t.co/nP8vObFsOH https://t.co/DuXQMyeaE3

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of Calcium Pyrophosphate Deposition Disease Lancet Rheumatology has published a review of Calcium pyrophosphate deposition (CPPD) disease - a chronic inflammatory and degenerative crystal arthropathy that increases with aging. https://t.co/svIGF3hM0Y https://t.co/17CNkOiGPB

Links:

Dr. John Cush RheumNow ( View Tweet)
Febuxostat is assoc w/ a reduced risk of kidney events and slower decline in eGFR. Metanalysis of 16 RCTs, shows febuxostat w/a reduced risk of kidney events (RR=0.56) & slower decline in eGFR; & reduced urine albumin to creatinine ratio https://t.co/GQ8UopbA88 https://t.co/WQskc1yZ02

Links:

Dr. John Cush RheumNow ( View Tweet)
Medscape review of new Gout research from EULAR 2024 - Phase 3 trial program for SEL-212 - Safety of SEL-212 - New Selective URAT1 Inhibitors - ruzinurad & AR882 https://t.co/szVRO2sqpu https://t.co/B9LcdpeCGd

Links:

Dr. John Cush RheumNow ( View Tweet)
Sobi has submitted a biologics license application to FDA for SEL-212 (pegadricase a uricase enzyme that breaks down uric acid) based on DISSOLVE I & II RCTs. SEL-212 was given FDA FDA’s Fast Track designation in March 2024 https://t.co/TPcUnCJOxT https://t.co/X1DrFDJZeK

Links:

Dr. John Cush RheumNow ( View Tweet)
POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0

Links:

TheDaoIndex KDAO2011 ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×